hypertension

The Australia-based startup wants to partner with drugmakers on biomarker-defined clinical trials and create clinical decision-support software.

Scores focused on the biochemical pathways associated with disease and pairing these scores with other risk assessments could improve predictive value, the data showed.

Investigators from Inserm and Radboud University Medical Center are spearheading the endeavor, called HT-Advance, which is funded by the EU, the UK, and Switzerland.